BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.94
+0.04 (0.40%)
At close: Jun 26, 2026, 4:00 PM EDT
10.02
+0.08 (0.80%)
After-hours: Jun 26, 2026, 7:53 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for BioCryst Pharmaceuticals stock have an average target of 22.88, with a low estimate of 13 and a high estimate of 32. The average target predicts an increase of 130.18% from the current stock price of 9.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 7, 2026.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +111.27% | May 7, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +181.69% | May 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $32 | Buy | Maintains | $32 | +221.93% | May 7, 2026 |
| Needham | Needham | Buy Maintains $18 → $16 | Buy | Maintains | $18 → $16 | +60.97% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 | Buy | Maintains | $30 | +201.81% | May 6, 2026 |
Financial Forecast
Revenue This Year
671.03M
from 874.84M
Decreased by -23.30%
Revenue Next Year
727.22M
from 671.03M
Increased by 8.37%
EPS This Year
0.57
from 0.63
Decreased by -10.98%
EPS Next Year
0.68
from 0.57
Increased by 20.35%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 732.5M | 775.8M | |
| Avg | 671.0M | 727.2M | |
| Low | 645.0M | 675.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -16.3% | 15.6% | |
| Avg | -23.3% | 8.4% | |
| Low | -26.3% | 0.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.73 | 1.10 | |
| Avg | 0.57 | 0.68 | |
| Low | 0.40 | 0.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 15.0% | 94.7% | |
| Avg | -11.0% | 20.4% | |
| Low | -37.0% | -20.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.